BN
BNTC.US Benitec Biopharma Inc.
- Market cap
- USD 315M
- P/E
- -
- P/B
- 1.80x
- ROE
- -30.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is BNTC.US undervalued?
Graham numberThe Graham number of Benitec Biopharma Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Benitec Biopharma Inc. fundamental analysis
No fundamental analysis for Benitec Biopharma Inc. yet.
Benitec Biopharma Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The comp…
Full company profileBenitec Biopharma Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Benitec Biopharma Inc. annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 196K | 4.40M | 17.4M | 97.0K | 59.0K | 73.0K | 75.0K | 216K | 0.00 | 0.00 | - |
| Gross Profit | 35.9K | 3.95M | 15.9M | 282K | -64.0K | 64.0K | 75.0K | -343K | -396K | -481K | - |
| Operating Income | -15.9M | -8.73M | 3.69M | -8.28M | -13.6M | -17.9M | -19.1M | -22.5M | -41.8M | -51.2M | -57.9M |
| EBITDA | -3.12M | -16.5M | 2.03M | -7.91M | -13.5M | -17.8M | -18.7M | -21.7M | -41.4M | -50.7M | -51.6M |
| Net Income | -5.60M | -12.3M | 3.73M | -8.27M | -13.9M | -18.2M | -19.6M | -21.8M | -37.9M | -45.5M | -51.7M |
| EPS | -41 | -75 | 19 | -34 | -14 | -9.47 | -14 | -5.36 | -1.05 | -0.98 | -1.04 |
| Balance Sheet | |||||||||||
| Total Assets | 22.7M | 21.4M | 27.5M | 11.7M | 21.4M | 5.97M | 4.46M | 52.2M | 99.6M | 183M | 179M |
| Total Liabilities | 891K | 2.61M | 2.64M | 1.51M | 1.37M | 3.09M | 4.26M | 4.96M | 2.30M | 5.61M | 9.45M |
| Shareholders' Equity | 21.6M | 13.8M | 16.6M | 10.2M | 20.0M | 2.88M | 202K | 47.2M | 97.3M | 177M | 170M |
| Cash & Short-term Investments | 17.4M | 16.2M | 22.5M | 9.80M | 19.8M | 4.06M | 2.48M | 50.9M | 97.7M | 180M | 176M |
| Total Debt | 0.00 | 0.00 | 0.00 | 405K | 213K | 811K | 559K | 284K | 849K | 762K | 642K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.30M | -9.79M | 4.79M | -7.54M | -12.8M | -15.9M | -18.0M | -19.4M | -23.6M | -16.5M | -14.5M |
| Capital Expenditure | 131K | 61.0K | 403K | 95.0K | 221K | 13.0K | 1.00K | 179K | 18.0K | 105K | 0.00 |
| Free Cash Flow | -8.44M | -8.61M | 4.39M | -7.63M | -13.1M | -15.9M | -18.0M | -19.6M | -23.6M | -16.6M | -14.5M |
| Ratios | |||||||||||
| ROE | -26.0% | -89.5% | 22.5% | -80.8% | -69.4% | -631.8% | -9,684.2% | -46.0% | -39.0% | -25.7% | -30.5% |
| ROA | -24.6% | -57.5% | 13.6% | -70.5% | -64.9% | -304.8% | -438.2% | -41.7% | -38.1% | -24.9% | -28.9% |
| Net Profit Margin | -2,860.4% | -280.1% | 21.4% | -8,529.9% | -23,528.8% | -24,942.5% | -26,082.7% | -10,069.9% | - | - | - |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.04x | 0.01x | 0.28x | 2.77x | 0.01x | 0.01x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Benitec Biopharma Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | AUD 619K | 0.15 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:17 on Jul 26, 2023.
Who owns Benitec Biopharma Inc.
- Insiders 0.55%
- Institutions 96.19%
- Public & others 3.27%
- Shares outstanding 34.9M
- Free float 20.0M
Top funds holding BNTC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HBM Healthcare Investments AG Ord | 1.19M | 3.42% | 0.00% | Sep 2026 |
| Simplify Health Care ETF | 1.12M | 3.21% | +3.04% | Oct 2026 |
| Franklin Biotechnology Discv A(acc)USD | 997K | 2.86% | 0.00% | Sep 2026 |
| Franklin Biotechnology Discovery A | 995K | 2.85% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 650K | 1.86% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 522K | 1.50% | 0.00% | Oct 2026 |
| Franklin Small Cap Growth Adv | 358K | 1.02% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 235K | 0.67% | +0.70% | Aug 2026 |
| iShares Russell 2000 Value ETF | 188K | 0.54% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 150K | 0.43% | +18.90% | Sep 2026 |
| MEDICAL BioHealth EUR Acc | 142K | 0.41% | -27.25% | Aug 2026 |
| Vanguard Russell 2000 ETF | 124K | 0.36% | +1.64% | Sep 2026 |
| iShares Micro-Cap ETF | 64.0K | 0.18% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 53.4K | 0.15% | +39.00% | Sep 2026 |
| RIM Global Bioscience EUR | 52.7K | 0.15% | 0.00% | Jul 2026 |
| Schwab Small Cap Index | 51.7K | 0.15% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 43.4K | 0.12% | -0.05% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 41.9K | 0.12% | 0.00% | Sep 2026 |
| Global X Genomics & Biotech ETF USD Acc | 34.9K | 0.10% | +0.42% | Oct 2026 |
Top institutions holding BNTC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 11.5M | 33.10% | 0.00% | Jun 2026 |
| Nantahala Capital Management, LLC | 2.98M | 8.53% | +106.95% | Jun 2026 |
| Jupiter Topco LLC | 2.48M | 7.10% | 0.00% | Jun 2026 |
| Franklin Templeton Inc | 2.41M | 6.92% | +1.46% | Jun 2026 |
| Adage Capital Partners Gp LLC | 2.12M | 6.08% | 0.00% | Jun 2026 |
| RA Capital Management, LLC | 1.85M | 5.30% | 0.00% | Jun 2026 |
| BlackRock Inc | 1.41M | 4.03% | +18.67% | Jun 2026 |
| Simplify Asset Management Inc. | 1.00M | 2.87% | -0.33% | Sep 2026 |
| Vanguard Capital Management, LLC | 955K | 2.74% | +2.47% | Jun 2026 |
| Millennium Management LLC | 921K | 2.64% | +41.29% | Jun 2026 |
| Alyeska Investment Group, L.P. | 750K | 2.15% | 0.00% | Jun 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 680K | 1.95% | -5.28% | Jun 2026 |
| Balyasny Asset Management LLC | 651K | 1.86% | -0.51% | Jun 2026 |
| Geode Capital Management, LLC | 612K | 1.75% | +16.72% | Jun 2026 |
| Ameriprise Financial Inc | 401K | 1.15% | -1.84% | Jun 2026 |
| State Street Corp | 378K | 1.08% | +11.74% | Jun 2026 |
| MYDA Advisors LLC | 250K | 0.72% | +11.11% | Jun 2026 |
| Schonfeld Strategic Advisors LLC | 235K | 0.67% | +53.65% | Jun 2026 |
| Awm Investment Company Inc | 188K | 0.54% | 0.00% | Jun 2026 |
| Northern Trust Corp | 178K | 0.51% | +13.42% | Jun 2026 |
Benitec Biopharma Inc. company profile
- Company name
- Benitec Biopharma Inc.
- Ticker
- BNTC.US
- Exchange
- USA Stocks
- Listed since
- Aug 18, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 24
- Fiscal year end
- June
- Address
- 3940 Trust Way, Hayward, CA, United States, 94545
- Phone
- 510 780 0819
- Website
- benitec.com
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Benitec Biopharma Inc. management
5- Dr. Jerel A. Banks M.D., Ph.D.Executive Chairman & CEO · born 1975
- Ms. Megan Joan Boston B.Com., C.A.CFO & Secretary · born 1972
- Ms. Sophie MukadamChief Operating Officer · born 1981
- Dr. Michael GrahamHead of Discovery & Founding Scientist
- Dr. Claudia Kloth Ph.D.Senior Vice President of Manufacturing